Aβ42 gene vaccine prevents Aβ42 deposition in brain of double transgenic mice

Journal of the Neurological Sciences

Volumn 260, Issue 1-2, 2007, Pages 204-213

  Qu, Bao Xi ^a   Xiang, Qun ^a   Li, Liping ^a   Johnston, Stephen Albert ^b   Hynan, Linda S ^c   Rosenberg, Roger N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Abeta Amyloid beta; AD Alzheimer's disease; APPswe PS1deltaE9 Amyloid precursor protein(Swedish mutation) presenilin 1 deltaE9 mutation; ELISPOT Enzyme linked immunosorbent spot; nm nanometer; SPSS Statistical Package for the Social Sciences

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; IMMUNOGLOBULIN G1 ANTIBODY; PLASMID DNA; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; IMMUNOGLOBULIN G; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTIBODY PRODUCTION; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE GUN; GLIA CELL; HIPPOCAMPUS; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN AGGREGATION; QUANTITATIVE ANALYSIS; RHESUS MONKEY; TH2 CELL; TRANSGENIC MOUSE; ACTIVE IMMUNIZATION; ANIMAL; BIOLISTIC TRANSFORMATION; BIOSYNTHESIS; BRAIN; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; GLIOSIS; IMMUNOLOGY; MACACA; METABOLISM; METHODOLOGY; PATHOLOGY; SENILE PLAQUE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIOLISTICS; BRAIN; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; GLIOSIS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; MACACA MULATTA; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; SENILE PLAQUES; TH2 CELLS; TREATMENT OUTCOME;

EID: 34547688911     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.05.012     Document Type: Article

References (34)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81 (2001) 741-766
2. Rosenberg R.N. The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture. Neurology 54 (2000) 2045-2054
3. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
4. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258 (1992) 126-129
5. Lahiri D.K., and Ge Y.W. Role of the APP promoter in Alzheimer's disease: cell type-specific expression of the beta-amyloid precursor protein. Ann NY Acad Sci 1030 (2004) 310-316
6. Fox N.W., Johnstone E.M., Ward K.E., Schrementi J., and Little S.P. APP gene promoter constructs are preferentially expressed in the CNS and testis of transgenic mice. Biochem Biophys Res Commun 240 (1997) 759-762
7. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., and Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13 (1994) 45-53
8. Iwatsubo T., Mann D.M., Odaka A., Suzuki N., and Ihara Y. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol 37 (1995) 294-299
9. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16 (1996) 921-932
10. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
11. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
12. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3 (2002) 824-828
13. Rosenberg R.N. Immunization with β-Amyloid(1-42) protein for Alzheimer disease: genomics predicts the response. JAMA 294 (2005) 2352-2353
14. Qu B., Rosenberg R.N., Li L., Boyer P.J., and Johnston S.A. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 61 (2004) 1859-1864
15. Qu B., Boyer P.J., Johnston S.A., Hynan L.S., and Rosenberg R.N. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci 244 (2006) 151-158
16. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 100 (2003) 2023-2028
17. Bachmann M.F., Kalinke U., Althage A., Freer G., Burkhart C., Roost H., et al. The role of antibody concentration and avidity in antiviral protection. Science 276 (1997) 2024-2027
18. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (2005) 1563-1572
19. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
20. Czerkinsky C.C., Tarkowski A., Nilsson L.A., Ouchterlony O., Nygren H., and Gretzer C. Reverse enzyme-linked immunospot assay (RELISPOT) for the detection of cells secreting immunoreactive substances. J Immunol Methods 72 (1984) 489-496
21. Torres K.C., Dutra W.O., and Gollob K.J. Endogenous IL-4 and IFN-gamma are essential for expression of Th2, but not Th1 cytokine message during the early differentiation of human CD4+ T helper cells. Hum Immunol 65 (2004) 1328-1335
22. Nakamura T., Kamogawa Y., Bottomly K., and Flavell R.A. Polarization of IL-4- and IFN-gamma-producing CD4+ T cells following activation of naive CD4+ T cells. J Immunol 158 (1997) 1085-1094
23. Monsonego A., Zota V., Karni A., Krieger J.I., Bar-Or A., Bitan G., et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112 (2003) 415-422
24. Dong Y., and Benveniste E.N. Immune function of astrocytes. Glia 36 (2001) 180-190
25. Tani M., Glabinski A.R., Tuohy V.K., Stoler M.H., Estes M.L., and Ransohoff R.M. In situ hybridization analysis of glial fibrillary acidic protein mRNA reveals evidence of biphasic astrocyte activation during acute experimental autoimmune encephalomyelitis. Am J Pathol 148 (1996) 889-896
26. Eng L.F., and Ghirnikar R.S. GFAP and astrogliosis. Brain Pathol 4 (1994) 229-237
27. Marinkovic T., Garin A., Yokota Y., Fu Y.X., Ruddle N.H., Furtado G.C., et al. Interaction of mature CD3+ CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. J Clin Invest 116 (2006) 2622-2632
28. Okura Y., Miyakoshi A., Kohyama K., Park K., Staufenbiel M., and Matsumoto Y. Nonviral Aβ DNA vaccine therapy against Alzheimer's disease: long term effects and safety. Proc Natl Acad Sci U S A 103 (2006) 9619-9624
29. Kumar A., Weiss W., Tine J.A., Hoffman S.L., and Rogers W.O. ELISPOT assay for detection of peptide specific interferon-gamma secreting cells in rhesus macaques. J Immunol Methods 247 (2001) 49-60
30. Vanderstichele H., Van Kerschaver E., Hesse C., Davidsson P., Buyse M.A., Andreasen N., et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7 (2000) 245-258
31. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 94 (1997) 1550-1555
32. Ghochikyan A., Vasilevko V., Petrushina I., Movsesyan N., Davit B., Tian W., et al. Generation and characterization of the humoral immune response to DNA immunization with chimeric β-amyloid-interleukin-4 minigene. Eur J Immunol 33 (2003) 3232-3241
33. Agadjanyan M., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174 (2005) 1580-1586
34. Schultz J., Salzer U., Mohajeri M., Franke D., Heinrich J., Pavlovic J., et al. Antibodies form a DNA peptide vaccination decrease brain amyloid burden in a mouse model of Alzheimer's disease. J Mol Med 82 (2004) 706-714